Study S001376

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg/m2) Without Comorbidities

ClinicalTrials.gov record

Registration

Registration: NCT07838740
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: RECRUITING
Enrollment: 270
Start: 2025-11-18
Primary completion: 2027-05
Lead sponsor: Viking Therapeutics, Inc.
Conditions: Obese Adults
Interventions: DRUG:VK2735 Drug; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Evaluate the Safety and Tolerability VK2735 [33 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.